C

Cyclerion Therapeutics
D

CYCN

3.19000
USD
-0.04
(-1.09%)
Market Closed
Volume
1
EPS
-1
Div Yield
-
P/E
-3
Market Cap
9,764,411
Related Instruments
ALNY
ALNY
0.47
(0.16%)
289.82 USD
AMGN
AMGN
-0.04
(-0.01%)
271.89 USD
A
ARWR
-0.250
(-1.62%)
15.140 USD
BMY
BMY
-0.140
(-0.30%)
46.870 USD
GSK
GSK
-0.560
(-1.43%)
38.690 USD
LLY
LLY
-7.85
(-1.09%)
713.61 USD
MRK
MRK
-0.220
(-0.28%)
77.600 USD
NVS
NVS
0.240
(0.21%)
112.750 USD
PFE
PFE
0.110
(0.47%)
23.330 USD
R
RCKT
-0.28500
(-4.35%)
6.26500 USD
More
News

Title: Cyclerion Therapeutics

Sector: Healthcare
Industry: Biotechnology
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.